Page last updated: 2024-11-05

triazolam and Diplopia

triazolam has been researched along with Diplopia in 1 studies

Triazolam: A short-acting benzodiazepine used in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries.

Diplopia: A visual symptom in which a single object is perceived by the visual cortex as two objects rather than one. Disorders associated with this condition include REFRACTIVE ERRORS; STRABISMUS; OCULOMOTOR NERVE DISEASES; TROCHLEAR NERVE DISEASES; ABDUCENS NERVE DISEASES; and diseases of the BRAIN STEM and OCCIPITAL LOBE.

Research Excerpts

ExcerptRelevanceReference
" The peak concentration was 4."2.70Pharmacokinetics and clinical effects of sublingual triazolam in pediatric dental patients. ( Coldwell, SE; Kaakko, T; Kharasch, ED; Milgrom, P; Spieker, M; Tweedy, CM, 2001)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Tweedy, CM1
Milgrom, P1
Kharasch, ED1
Kaakko, T1
Spieker, M1
Coldwell, SE1

Trials

1 trial available for triazolam and Diplopia

ArticleYear
Pharmacokinetics and clinical effects of sublingual triazolam in pediatric dental patients.
    Journal of clinical psychopharmacology, 2001, Volume: 21, Issue:3

    Topics: Administration, Sublingual; Amnesia; Anti-Anxiety Agents; Area Under Curve; Ataxia; Child; Child, Pr

2001